Always up to date! 

Unser Ziel ist es, behandlungs- und anatomiespezifische Implantate zu entwickeln, die in Zusammenarbeit mit unseren Kunden zu berechenbaren und besseren Behandlungsergebnissen führen. Lesen Sie weiter, um mehr über unsere Lösungen, Prioritäten und Partnerschaften zu erfahren und darüber, wie wir mit unseren Teams nachhaltig Wert schaffen.

Medartis completes acquisition of Nextremity Solutions Inc. and announces new US leadership

Basel, Switzerland, 3 May 2022 - Medartis Holding AG (SIX: MED) announced today that it has completed the acquisition of Nextremity Solutions Inc., a strategic commercialisation organisation located...

Weiterlesen

Medartis has decided not to pursue the convertible bond placement

Ad hoc announcement pursuant to Art. 53 LR

Basel, 8 April 2022: The Board of Medartis has decided not to pursue the planned convertible bond placement, which was announced on Thursday evening. The...

Weiterlesen

Medartis has decided not to pursue the convertible bond placement

Basel, 8 April 2022: The Board of Medartis has decided not to pursue the planned convertible bond placement, which was announced on Thursday evening. The bookbuilding exercise generated a substantial...

Weiterlesen

Medartis launches senior convertible bond offering with a target size of CHF 125-150 million

Ad hoc announcement pursuant to Art. 53 LR

Basel, 7 April 2022: Medartis Holding AG (SIX: MED, the “Issuer” or “Medartis”), a specialized orthopaedic company for head and extremity surgery, announces...

Weiterlesen

Medartis launches senior convertible bond offering with a target size of CHF 125-150 million

Basel, 7 April 2022: Medartis Holding AG (SIX: MED, the “Issuer” or “Medartis”), a specialized orthopaedic company for head and extremity surgery, announces today the launch of a senior unsecured...

Weiterlesen

Medartis shareholders approve all proposals of the Board of Directors

    Ad hoc announcement pursuant to Art. 53 LR
  • 84.8% of the total share capital was represented at this year's Annual General Meeting
  • All proposals of the Board of Directors were approved with a...
Weiterlesen

Medartis shareholders approve all proposals of the Board of Directors

  • 84.8% of the total share capital was represented at this year's Annual General Meeting
  • All proposals of the Board of Directors were approved with a large majority
  • Ms. Nadia Tarolli Schmidt...
Weiterlesen

Medartis akquiriert Nextremity Solutions Inc.

Wir freuen uns, die Übernahme von Nextremity Solutions Inc. bekannt zu geben, einem orthopädischen Unternehmen mit Sitz in Warsaw (USA), das Produkte zur Behandlung von Knochenbrüchen und...

Weiterlesen

Strong sales growth and further margin improvements – important acquisition to accelerate the US extremities business

  • Total net sales increased by 24.8% year-on-year at CER[1]
  • All regions grew by more than 20% CER – 29% growth in the US and 22% in EMEA
  • Strong growth led to higher margins at all levels  EBITDA...
Weiterlesen

Medartis 2021 full-year results presentation

Dear ladies and gentlemen

We are pleased to invite you to our FY 2021 results presentation on 7 March 2022. We will publish our media release, the Annual Report, and the conference presentation on...

Weiterlesen